U.S. Markets close in 1 hr 37 mins
  • S&P 500

    3,674.89
    +53.26 (+1.47%)
     
  • Dow 30

    29,922.91
    +284.27 (+0.96%)
     
  • Nasdaq

    12,394.20
    +195.46 (+1.60%)
     
  • Russell 2000

    1,841.80
    +21.99 (+1.21%)
     
  • Crude Oil

    44.50
    -0.84 (-1.85%)
     
  • Gold

    1,817.80
    +36.90 (+2.07%)
     
  • Silver

    24.09
    +1.50 (+6.65%)
     
  • EUR/USD

    1.2055
    +0.0121 (+1.0127%)
     
  • 10-Yr Bond

    0.9340
    +0.0900 (+10.66%)
     
  • Vix

    20.42
    -0.15 (-0.73%)
     
  • GBP/USD

    1.3422
    +0.0090 (+0.6778%)
     
  • USD/JPY

    104.3700
    +0.0460 (+0.0441%)
     
  • BTC-USD

    18,950.68
    -449.09 (-2.31%)
     
  • CMC Crypto 200

    372.07
    -7.79 (-2.05%)
     
  • FTSE 100

    6,384.73
    +118.54 (+1.89%)
     
  • Nikkei 225

    26,787.54
    +353.92 (+1.34%)
     

Recap: Inspire Medical Systems Q3 Earnings

Benzinga Insights
·1 min read

Shares of Inspire Medical Systems (NYSE:INSP) rose 9.53% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 14.71% over the past year to ($0.39), which beat the estimate of ($0.72).

Revenue of $35,842,000 higher by 71.81% from the same period last year, which beat the estimate of $22,750,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

The upcoming fiscal year's revenue expected to be between $110,000,000 and $112,000,000.

Details Of The Call

Date: Nov 02, 2020

View more earnings on INSP

Time: 05:00 PM

ET Webcast URL: http://public.viavid.com/player/index.php?id=141564

Price Action

Company's 52-week high was at $135.20

Company's 52-week low was at $40.53

Price action over last quarter: Up 11.81%

Company Profile

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.